Soliris 300 MG/30 ML vial 30ML
Ended Awarded
- Contract number
- SPE2DR26FMDY0
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $41,008
Award facts
- Contract value 100% obligated
- $41,008.16 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $41,008.16 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Soliris 300 mg/30 ml vials. The award, issued on November 18, 2025, with an ultimate completion date of December 10, 2025, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This delivery order was issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, designated as contract SPE2DR, which was established on November 13, 2025.
The PPV-G GEN V represents a $30.3 billion acquisition strategy through which the Defense Logistics Agency establishes multiple regional prime vendor contractors to supply comprehensive pharmaceutical products and medical consumables supporting Department of Defense healthcare operations globally. DMS Pharmaceutical Group's IDC carries a ceiling value of $499,999,999 with a 30-month base period and three 30-month option periods extending through December 31, 2036. The company's established performance across diverse product categories—including specialty pharmaceuticals, biologics, vaccines, and emergency medications—positions it as a critical pharmaceutical supplier for military healthcare facilities worldwide.
Quick answers
Who was awarded contract SPE2DR26FMDY0?
SPE2DR26FMDY0 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 18, 2025.
How much is contract SPE2DR26FMDY0 worth?
The government has obligated $41,008 on SPE2DR26FMDY0.
Is contract SPE2DR26FMDY0 an order under another contract?
Yes. SPE2DR26FMDY0 is a delivery order under SPE2DR25D9114, an indefinite delivery contract.
Was contract SPE2DR26FMDY0 competed?
The extent of competition for SPE2DR26FMDY0 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award